ArticleJournal of clinical practice and research2025
Effectiveness and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Patients Diagnosed with Chronic Hepatitis C.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study aimed to evaluate the effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) treatment in patients infected with hepatitis C virus (HCV). Materials and Methods: Forty-four patients who applied to the Infectious Diseases and Clinical Microbiology Clinic between December 2019 and December 2022 were infected with HCV genotype 1-6 and came regularly for treatment and follow-up visits were included in the study. The study was conducted retrospectively by accessing patient data through the hospital information management system. In patients receiving GLE/PIB treatment, data regarding the effectiveness and reliability of the treatment were recorded both during the treatment process and after the treatment was terminated. Results: Of the 44 patients, 47.7% were genotype 1b, 18.2% were genotype 1a, 15.9% were genotype 2, 13.6% were genotype 4, and 4.5% were infected with genotype 3. Early virological response (EVR) was achieved in 81.8% of 44 patients. End-of-treatment response and sustained virological response at the 12 Conclusion: The GLE/PIB combination is an effective and safe treatment option in the treatment of HCV infection. Due to the high EVR rates, more comprehensive studies need to be conducted to keep the duration of GLE/PIB treatment shorter in some patient groups in patients diagnosed with CHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.